February 2020

Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.

A session on the use of biosimilars, a topic that many pharmacists identify to be of growing importance in their practices, concluded the 2019 Directions in Oncology Pharmacy conference.

PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.

With cases of melanoma increasing more rapidly than those of other malignancies (especially in men), no conference on oncology pharmacy would be complete without a session covering this topic and its expansion of treatment options.

Many people are unaware that acute myeloid leukemia (AML) is the leading cause of acute leukemia in adults.

Approximately 73,000 NEW cases of renal cell carcinoma (RCC) are expected to be diagnosed in 2019 in the United States, with up to 70% of these cases anticipated to be clear-cell subtype.

Asembia's 2020 Specialty Pharmacy Summit (May 3-7 at the Wynn & Encore in Las Vegas) will bring together stakeholders from across the industry to investigate challenges and collectively generate solutions.

Oncologists have grown increasingly concerned that high costs create ‘financial toxicity’ and may keep patients from getting needed treatments.

Prior authorization (PA) requirements, cost, and other factors can lead to turnaround times of up to 3 weeks, delaying the start of therapy and creating substantial anxiety for patients.

Patients with CLL may have genetic mutations that predict response to different treatments.

Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.

As the growth of specialty continues at a record pace, pharmacy must keep up with new distribution trends as an oncology product’s supply chain of a product can take many paths.

HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.

To stay up-to-date on the latest in oncology pharmacy, make sure to check out the slate of programming that will be offered this year through our Directions in Oncology PharmacyTM series.

Guidelines indicate that there are a number of treatment options for head and neck cancers.